Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV
NCT07569029Phase 1Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2026
- Primary completion
- Aug 2027
- Modality
- RNA Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
Phase 1, open-label trial of DV700P-RNA and DV701B1.1-RNA in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Local reactogenicity following study product administration, Systemic reactogenicity following study product administration and 7 more. Started Sep 2026; status: recruiting.
02
Drugs
DV700P-RNADV701B1.1-RNA
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07569029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07569029.